Current Report Filing (8-k)
May 21 2020 - 3:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): May 21, 2020
Seneca
Biopharma, Inc.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
001-33672
|
|
52-2007292
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2 nd
Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
Title of Class
|
|
Trading Symbol
|
|
Name of Each Exchange on Which Registered
|
Common stock, par value $0.01 per share
|
|
SNCA
|
|
NASDAQ Capital Market
|
|
Item 7.01
|
Regulation FD Disclosure.
|
As of May 21, 2020, Seneca Biopharma, Inc.
has 12,299,307 shares of its common stock, par value $0.01, issued and outstanding.
The information contained in this Item
7.01 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor
shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: May 21, 2020
|
Seneca Biopharma, Inc.
|
|
|
|
|
|
|
|
|
/s/ Kenneth Carter
|
|
|
By: Kenneth Carter
|
|
|
Executive Chairman
|
|
|
|
|
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024